Research programme: drug discovery - BioFocus DPI/Ono Pharmaceuticals
Latest Information Update: 15 Apr 2014
At a glance
- Originator BioFocus DPI; Ono Pharmaceutical
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 18 Apr 2007 Preclinical trials in Undefined indication in Europe (unspecified route)